InvestSMART

Tryptamine Therapeutics Limited (ASX: TYP) - Share Price

Current share price for TYP : $0.034 0.002 (5.56%)+

TYP General Information +

ASX Code TYP
Website N/A
Industry/Sector n/a
Market Cap ($M) n/a
TYP Share Price $0.034
Day High $0.035
Day Low $0.032
Last Close $0.036
TYP Share Price Movement $0.00 ( 5.56% )
Prices as at 16:41, 20 Nov 2025
+Security prices are delayed by at least 20 minutes and are indicative only.

Tryptamine Therapeutics Limited (TYP) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Tryptamine Therapeutics Limited (TYP) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Tryptamine Therapeutics Limited (TYP) price-sensitive announcements

TYP - BED trial accelerates - enrolment grows, dosing in two weeks
Tryptamine Therapeutics Limited ('Tryp') has made significant progress in its clinical tri
Tryptamine Therapeutics Limited (TYP)
18 Nov 2025 | 8:55 AM
TYP - $6.1m in new funding to accelerate clinical development
Tryptamine Therapeutics Limited (Tryp), a clinical-stage biotechnology company based in Me
Tryptamine Therapeutics Limited (TYP)
5 Nov 2025 | 9:38 AM
TYP - Trading Halt
Tryptamine Therapeutics Limited (ASX: TYP) has requested a trading halt on its ordinary sh
Tryptamine Therapeutics Limited (TYP)
3 Nov 2025 | 9:22 AM
TYP - Quarterly Activities Report and Appendix 4C
Tryptamine Therapeutics Limited (ASX: TYP) provided an update on their clinical and commer
Tryptamine Therapeutics Limited (TYP)
31 Oct 2025 | 6:19 PM

Tryptamine Therapeutics Limited (TYP) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Tryptamine Therapeutics Limited (TYP)
ORDINARY FULLY PAID
Health Care - Cleansing Notice 18 Nov 2025 10:21AM $0.035 $0.034 fallen by 2.86%
Tryptamine Therapeutics Limited (TYP)
ORDINARY FULLY PAID
Health Care - Application for quotation of securities - TYP 18 Nov 2025 10:10AM $0.035 $0.034 fallen by 2.86%
Tryptamine Therapeutics Limited (TYP)
ORDINARY FULLY PAID
Health Care - BED trial accelerates - enrolment grows, dosing in two weeks 18 Nov 2025 8:55AM $0.036 $0.034 fallen by 5.56%
Tryptamine Therapeutics Limited (TYP)
ORDINARY FULLY PAID
Health Care - Change of Registered Office & Principal Place of Business 14 Nov 2025 9:43AM $0.036 $0.034 fallen by 5.56%
Tryptamine Therapeutics Limited (TYP)
ORDINARY FULLY PAID
Health Care - Results of AGM 13 Nov 2025 4:54PM $0.036 $0.034 fallen by 5.56%
Tryptamine Therapeutics Limited (TYP)
ORDINARY FULLY PAID
Health Care - Notification of cessation of securities - TYP 11 Nov 2025 3:42PM $0.038 $0.034 fallen by 10.53%

Tryptamine Therapeutics Limited (TYP) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
2 Oct 2024 CARROLL, Jason Buy Direct Shares 550,000 $0.018 $9,900.000
14 Jun 2024 CARROLL, Jason Buy Direct Shares 604,738 $0.020 $11,990.020
6 Jun 2024 CARROLL, Jason Buy Direct Shares 1,692,514 $0.021 $36,090.040

See all changes in directors' interest & trades for Tryptamine Therapeutics Limited (TYP) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.